Breast Cancer | Specialty

Dr. Borgen Discusses Axillary Node Dissection in Early-Stage Breast Cancer

August 7th 2018

Patrick I. Borgen, MD, chairman of surgery, director of the Breast Cancer Program, Maimonides Medical Center, discusses axillary node dissection in patients with early-stage breast cancer.

Dr. Murthy on Dual HER2 Blockade in HER2+ Breast Cancer

August 6th 2018

Rashmi K. Murthy, MD, assistant professor, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses dual HER2 blockade in HER2-positive breast cancer.

Dana-Farber Researcher Sees Biomarker Potential in ESR1 Mutations

August 3rd 2018

Rinath M. Jeselsohn, MD, discusses the detection and clinical implications of ESR1 mutations.

Yardley Recaps Breast Cancer Data From ASCO 2018

August 2nd 2018

Denise A. Yardley, MD, weighs in on the recent data reported in breast cancer.

Dr. Murthy on Future of Tucatinib in HER2+ Breast Cancer

August 1st 2018

Rashmi K. Murthy, MD, assistant professor, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the future of tucatinib in HER2-positive breast cancer.

ESR1 Mutations Take Center Stage in Metastatic ER-Positive Breast Cancer

August 1st 2018

Despite gaps in current knowledge, investigators are already working toward the development of novel treatment strategies to combat the effects of ESR1 mutations.

Dr. Ligibel on the Impact of Diet and Exercise on Breast Cancer Recurrence Risk

August 1st 2018

Jennifer Ligibel, MD, senior physician, Susan F. Smith Center for Women’s Cancer at the Dana-Farber Cancer Institute, discusses the impact of diet and exercise on the risk of breast cancer recurrence.

Dr. Ellis on Abemaciclib in HR-Positive Breast Cancer

August 1st 2018

Matthew J. Ellis, MD, PhD, professor and director, Lester and Sue Smith Breast Center, associate director of precision medicine, Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, discusses the use of abemaciclib (Verzenio) in hormone receptor-positive breast cancer.

Dr. Adams on Combinatorial Approaches in Triple-Negative Breast Cancer

August 1st 2018

Sylvia Adams, MD, associate professor, Department of Medicine, director, Clinical Research, Breast Cancer Disease Management Group, NYU Langone’s Perlmutter Cancer Center, discusses combinatorial approaches in triple-negative breast cancer.

Dr. Yardley on the D-CARE Trial in Women With High-Risk Early Breast Cancer

July 31st 2018

Denise A. Yardley, MD, senior investigator of breast cancer research, Sarah Cannon Research Institute, discusses the D-CARE trial in women with high-risk early breast cancer.

Dr. Yee on Neoadjuvant Therapy for Triple-Negative Breast Cancer

July 30th 2018

Douglas Yee, MD, professor of medicine and pharmacology, Hematology, Oncology and Transplant, medical oncologist, University of Minnesota, discusses neoadjuvant therapy for patients with triple-negative breast cancer.

Dr. Sparano on Application of Liquid Biopsies in Breast Cancer

July 30th 2018

Joseph A. Sparano, MD, associate director for clinical research, Albert Einstein Cancer Center, Montefiore Medical Center, discusses the application of liquid biopsies in breast cancer.

Wolmark's Passion for Evidence-Based Medicine Helped Transform Cancer Care

July 30th 2018

Norman Wolmark, MD, a 2017 Giants of Cancer Care® award winner in the Breast Cancer category, played a pivotal role in building the clinical trials program at the National Surgical Adjuvant Breast and Bowel Project.

Dr. Woodward on Proton Radiotherapy in Breast Cancer

July 27th 2018

Wendy A. Woodward, MD, PhD, professor and chief, Clinical Breast Radiotherapy Service, Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, discusses proton radiotherapy in breast cancer.

Immunotherapy Remains Focal Point in TNBC

July 27th 2018

Sylvia Adams, MD, discusses the path forward for immunotherapy in triple-negative breast cancer.

Dr. Esserman on Personalized Screenings for Breast Cancer

July 26th 2018

Laura Esserman, MD, MBA, professor, University of California, San Francisco, discusses personalized versus annual screenings for breast cancer.

Future of CDK4/6 Inhibition in HR+ Breast Cancer

July 26th 2018

Abemaciclib Monotherapy's Role in HR+ Breast Cancer

July 26th 2018

Optimizing CDK4/6 Inhibition in HR+ Breast Cancer

July 26th 2018

HR+ Breast Cancer: Factors in Selecting a CDK4/6 Inhibitor

July 26th 2018